Corvus Pharmaceuticals’ (CRVS) Buy Rating Reiterated at HC Wainwright

Corvus Pharmaceuticals (NASDAQ:CRVS)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They presently have a $11.00 price target on the stock. HC Wainwright’s price objective would suggest a potential upside of 111.54% from the company’s current price.

Other equities analysts have also recently issued reports about the company. Mizuho raised Corvus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 22nd. StockNews.com downgraded shares of Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, October 31st. LADENBURG THALM/SH SH raised their target price on shares of Corvus Pharmaceuticals from $12.00 to $21.00 and gave the stock a “buy” rating in a research report on Monday, September 16th. Finally, Oppenheimer lifted their target price on shares of Corvus Pharmaceuticals from $8.00 to $14.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. One analyst has rated the stock with a sell rating, four have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $12.38.

Corvus Pharmaceuticals Price Performance

Shares of NASDAQ:CRVS opened at $5.20 on Tuesday. The stock’s 50-day moving average is $7.28 and its 200 day moving average is $5.49. The company has a market cap of $334.14 million, a PE ratio of -5.59 and a beta of 1.07. Corvus Pharmaceuticals has a 1 year low of $1.30 and a 1 year high of $10.00.

Institutional Trading of Corvus Pharmaceuticals

Hedge funds have recently modified their holdings of the business. Samlyn Capital LLC lifted its position in Corvus Pharmaceuticals by 160.7% during the 2nd quarter. Samlyn Capital LLC now owns 6,123,021 shares of the company’s stock valued at $11,144,000 after acquiring an additional 3,774,658 shares during the period. Point72 Asset Management L.P. purchased a new stake in shares of Corvus Pharmaceuticals in the 2nd quarter worth approximately $10,855,000. Geode Capital Management LLC increased its position in Corvus Pharmaceuticals by 22.4% during the 3rd quarter. Geode Capital Management LLC now owns 563,009 shares of the company’s stock valued at $2,974,000 after buying an additional 102,869 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its stake in Corvus Pharmaceuticals by 64.7% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 137,031 shares of the company’s stock valued at $724,000 after buying an additional 53,809 shares during the last quarter. Finally, State Street Corp grew its stake in shares of Corvus Pharmaceuticals by 48.2% in the third quarter. State Street Corp now owns 178,246 shares of the company’s stock worth $941,000 after acquiring an additional 57,943 shares during the last quarter. Institutional investors own 46.64% of the company’s stock.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.